Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).
Study Type
OBSERVATIONAL
Enrollment
25
Adult patients (\>18 years) with Follicular Non-Hodgkin Lymphoma, who have undergone at least two lines of therapy, treated with Mosunetuzumab under a compassionate use program
IRCCS Ospedale San Raffaele
Milan, Italy
RECRUITINGEvaluate the response to Mosu (Lugano criteria)
The primary objective of the study is to evaluate the response to mosunetuzumab in patients diagnosed with follicular lymphoma from second-line therapy, within the national compassionate use program (CUP). This response is assessed according to the 2014 Lugano criteria.
Time frame: Up to 1 year from treatment initiation
Disease-free survival (PFS)
Disease-free survival (PFS) at 1 year is evaluated.
Time frame: 1 year after starting treatment (PFS at 1 year)
OS
The study's secondary objective is to evaluate the overall survival (OS) of the included patients.
Time frame: 12 month
rate of toxicity
Analyze the rate of toxicity recorded during therapy, with particular attention to infusion reactions, CRS, and ICANS.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.